NewcelX Emerges: A Major Merger in Biotechnology Industry The merger of NLS Pharmaceutics and Kadimastem marks a significant breakthrough in biotechnology, leading to the birth of NewcelX, focused on advanced therapies for neurodegenerative diseases.

NewcelX Emerges: A Major Merger in Biotechnology Industry #Switzerland #NLS_Pharmaceutics #Zurich #Kadimastem #NewCelX

NLS Pharmaceutics and Kadimastem Affirm Ongoing Support for ITOL-102 Diabetes Program Post-Merger NLS Pharmaceutics and Kadimastem announce ongoing BIRD Foundation support for the ITOL-102 diabetes therapy after their merger, indicating a brighter future.

NLS Pharmaceutics and Kadimastem Affirm Ongoing Support for ITOL-102 Diabetes Program Post-Merger #Switzerland #NLS_Pharmaceutics #Zurich #BIRD_Foundation #Kadimastem

NLS Pharmaceutics Announces Major Changes Ahead of Merger with Kadimastem NLS Pharmaceutics Ltd. reveals its plans for a reverse share split and a new identity as it prepares for its merger with Kadimastem, aiming for more streamlined operations.

NLS Pharmaceutics Announces Major Changes Ahead of Merger with Kadimastem #Switzerland #NLS_Pharmaceutics #Zurich #Kadimastem #NewcelX_Ltd.

NLS Pharmaceutics and Kadimastem Finalize Merger Conditions and New Listing Plans NLS Pharmaceutics and Kadimastem complete all necessary conditions for their merger and announce plans for listing on Nasdaq as NewCelX Ltd. after delisting from TASE.

NLS Pharmaceutics and Kadimastem Finalize Merger Conditions and New Listing Plans #Israel #NLS_Pharmaceutics #Zurich #Kadimastem #NewCelX

NLS Pharmaceutics and Kadimastem Form Strategic Alliance to Boost Gene-Edited Therapies NLS Pharmaceutics and Kadimastem's collaboration with TargetGene aims to advance next-gen gene-edited cell therapies for chronic diseases, including ALS.

NLS Pharmaceutics and Kadimastem Form Strategic Alliance to Boost Gene-Edited Therapies #Switzerland #NLS_Pharmaceutics #Zurich #Kadimastem #TargetGene

NLS Pharmaceutics and Kadimastem's Merger Gains Nasdaq Approval, Set for Closure by October 2025 NLS Pharmaceutics and Kadimastem have received Nasdaq approval for their merger, expected to close on October 30, 2025, reshaping the landscape of CNS therapies.

NLS Pharmaceutics and Kadimastem's Merger Gains Nasdaq Approval, Set for Closure by October 2025 #Switzerland #NLS_Pharmaceutics #Zurich #Kadimastem #NewCelX

NLS Pharmaceutics and Kadimastem to Create NewCelX Through Merger Approval NLS Pharmaceutics and Kadimastem successfully secure shareholder approval for their merger, establishing NewCelX as a Nasdaq-listed company focused on innovative therapies.

NLS Pharmaceutics and Kadimastem to Create NewCelX Through Merger Approval #Switzerland #NLS_Pharmaceutics #Zurich #Kadimastem #NewCelX

Kadimastem and NLS Pharmaceutics Announce SEC Clearance for Merger Completion Kadimastem and NLS Pharmaceutics have received SEC approval for their merger, paving the way for the establishment of NewCelX Ltd., focused on innovative therapies.

Kadimastem and NLS Pharmaceutics Announce SEC Clearance for Merger Completion #Switzerland #NLS_Pharmaceutics #Zurich #Kadimastem #NewCelX

NLS Pharmaceutics and Kadimastem Achieve Patent Milestone for Diabetes Cure in Hong Kong NLS Pharmaceutics and Kadimastem's recent patent grant in Hong Kong enhances their IsletRx technology, aiming to revolutionize diabetes treatment.

NLS Pharmaceutics and Kadimastem Achieve Patent Milestone for Diabetes Cure in Hong Kong #Switzerland #NLS_Pharmaceutics #Zurich #Kadimastem #IsletRx

NLS Pharmaceutics Advances iTOL-102 Program with New Funding and FDA Support for Type 1 Diabetes Therapy NLS Pharmaceutics announces advancement in the iTOL-102 diabetes program, following FDA guidance and new funding from the BIRD Foundation for cell therapy development.

NLS Pharmaceutics Advances iTOL-102 Program with New Funding and FDA Support for Type 1 Diabetes Therapy #Type_1_Diabetes #Switzerland #NLS_Pharmaceutics #Zurich #Kadimastem

NLS Pharmaceutics and Kadimastem Complete $1 Million Equity Financing Deal NLS Pharmaceutics announces the successful closing of a $1 million equity financing, furthering its merger plans with Kadimastem and strengthening their financial position.

NLS Pharmaceutics and Kadimastem Complete $1 Million Equity Financing Deal #Switzerland #NLS_Pharmaceutics #Zurich #Equity_Financing #Kadimastem

NLS Pharmaceutics CEO Outlines Significant Progress and Future Plans in Shareholder Letter NLS Pharmaceutics has outlined recent achievements and future plans in a letter to shareholders, emphasizing financing success and clinical advancements.

NLS Pharmaceutics CEO Outlines Significant Progress and Future Plans in Shareholder Letter #Clinical_Trials #Switzerland #NLS_Pharmaceutics #Zurich #Kadimastem

NLS Pharmaceutics Shares Plans for Strategic Growth Following Merger with Kadimastem NLS Pharmaceutics, a clinical-stage biopharmaceutical firm, outlines significant developments including a merger with Kadimastem and advancements in diabetes therapies.

NLS Pharmaceutics Shares Plans for Strategic Growth Following Merger with Kadimastem #biopharmaceuticals #Switzerland #NLS_Pharmaceutics #Zurich #Kadimastem

Kadimastem and iTolerance Achieve Key Milestone with FDA for Type 1 Diabetes Treatment Kadimastem and iTolerance's collaboration reaches a pivotal moment with FDA feedback on their diabetes treatment, iTOL-102, potentially eliminating lifelong immune suppression needs.

Kadimastem and iTolerance Achieve Key Milestone with FDA for Type 1 Diabetes Treatment #United_States #Miami #Type_1_Diabetes #Kadimastem #iTolerance

NLS Pharmaceutics and Kadimastem Collaborate to Revolutionize Diabetes Management with Innovative Multi-Target Solutions NLS Pharmaceutics and Kadimastem are set to change diabetes treatment with their unique approach, moving beyond traditional therapies for better patient outcomes.

NLS Pharmaceutics and Kadimastem Collaborate to Revolutionize Diabetes Management with Innovative Multi-Target Solutions #Switzerland #NLS_Pharmaceutics #Zurich #Kadimastem #diabetes_treatment

Kadimastem and NLS Pharmaceutics Merge to Create Leading Biotech Company Kadimastem's shareholders have approved a pivotal merger with NLS Pharmaceutics, aiming to form a leading biotechnology company focusing on neurodegenerative diseases.

Kadimastem and NLS Pharmaceutics Merge to Create Leading Biotech Company #biotechnology #Switzerland #NLS_Pharmaceutics #Zurich #Kadimastem

Kadimastem Moves Forward with Shareholders to Finalize Merger with NLS Pharmaceutics Kadimastem has called a special meeting to obtain shareholder approval for its merger with NLS Pharmaceutics, enhancing biopharmaceutical innovations.

Kadimastem Moves Forward with Shareholders to Finalize Merger with NLS Pharmaceutics #biopharmaceuticals #Switzerland #NLS_Pharmaceutics #Zurich #Kadimastem

NLS Pharmaceutics and Kadimastem Take Major Steps Towards Merger with SEC Filing NLS Pharmaceutics and Kadimastem are progressing toward a merger, filing an F-4 Registration with the SEC to outline their strategic partnership and future plans.

NLS Pharmaceutics and Kadimastem Take Major Steps Towards Merger with SEC Filing #biotechnology #Switzerland #NLS_Pharmaceutics #Zurich #Kadimastem